In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival by Brave, SR, Marshall, G, Wainwright, A, James, N, Acheson, N, Howard, Z, Ratcliffe, K, Speake, G, Barry, S, Hickinson, D, Ryan, A

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. by Smith, N, Baker, D, James, N, Ratcliffe, K, Jenkins, M, Ashton, SE, Sproat, G, Swann, R, Gray, N, Ryan, A, Jürgensmeier, J, Womack, C

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. by Brave, SR, Odedra, R, James, N, Smith, N, Marshall, G, Acheson, K, Baker, D, Howard, Z, Jackson, L, Ratcliffe, K, Wainwright, A, Lovick, S, Hickinson, D, Wilkinson, R, Barry, S, Speake, G, Ryan, A